[Teriparatide (parathyroid hormone) for treaing osteoporosis in women in post-menopause]

Department of Science and Technology - Brazilian Health Technology Assessment General Coordination
Record ID 32006001470
Authors' objectives:

To evaluate the effectiveness and safety of the recombinant human parathyroid hormone (Teriparatide) in the treatment of osteoporosis in the postmenopause.

Authors' recommendations: As administered in low doses (20mg) and intermittently Teriparatide seems to reduce vertebral (67%) and non-vertebral (38%) fractures, and increases the column and fermoral bone mineral density. Longer studies are necessary to provide conclusions about safety and persistence of therapeutical effects.
Project Status: Completed
Year Published: 2005
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Brazil
MeSH Terms
  • Female
  • Parathyroid Hormone
  • Bone Density Conservation Agents
  • Osteoporosis, Postmenopausal
  • Teriparatide
Organisation Name: Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
Contact Address: Ministerio da Saude, Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia, Esplanada dos Ministerios, Edificio sede; bl "G" - 8 andar - SL 834, CEP: 70058-900, Brasilia, DF Brazil, Tel: +55 61 3315 3197 Fax: +55 61 3315 3850
Contact Name: suzanne.jacob@saude.gov.br
Contact Email: suzanne.jacob@saude.gov.br
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.